Panos Fidias

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Patricia L. Harris, Allan Wissner, Thomas J Lynch, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Marek Ancukiewicz, Thomas J Lynch, Rakesh K Jain, 2015, Proceedings of the National Academy of Sciences.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

William Pao, Yumei Pan, Lu Wang, 2012, Proceedings of the National Academy of Sciences.